Valuation: Alkermes plc

Market Cap 8.62B 7.56B 6.98B 6.42B 12.12B 831B 12.31B 83.51B 32.74B 407B 32.37B 31.66B 1,401B P/E 2026 *
-135x
P/E 2027 * 88.8x
Enterprise Value 9.63B 8.44B 7.8B 7.17B 13.54B 929B 13.75B 93.28B 36.57B 454B 36.16B 35.37B 1,565B EV / Sales 2026 *
5.32x
EV / Sales 2027 * 4.96x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week-0.29%
Current month-1.29%
1 month+14.96%
3 months+51.10%
6 months+62.90%
Current year+84.85%
1 week 50.49
Extreme 50.4855
53.52
1 month 45
Extreme 45.005
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

Compliance Officer

-2,034 0.0012%
01/07/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
12/06/26 Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-0.29%+77.00%+61.78% 8.79B
-0.49%-4.01%-0.84%+2.28% 49.18B
-3.10%-1.94%+370.99%+572.60% 39.58B
-0.46%+2.18%+5.44%+61.01% 34.69B
-1.14%-1.76%+26.94%-9.93% 34.42B
-1.82%-1.43%+0.52%+31.85% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+69.28%+113.82% 15.36B
+1.17%+2.30%+15.87%+18.26% 14.05B
-2.25%+0.05%+15.77%-32.83% 13.02B
Average -1.53%-0.97%+64.55%+90.98% 25.24B
Weighted average by Cap. -1.45%-1.37%+75.95%+116.56%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.47B 1.35B 2.54B 175B 2.59B 17.53B 6.87B 85.39B 6.8B 6.65B 294B 1.89B 1.66B 1.53B 1.41B 2.66B 182B 2.7B 18.32B 7.18B 89.21B 7.1B 6.95B 307B
Net income -64.6M -56.62M -52.34M -48.14M -90.82M -6.23B -92.28M -626M -245M -3.05B -243M -237M -10.5B 100M 87.78M 81.14M 74.62M 141M 9.66B 143M 970M 380M 4.73B 376M 368M 16.28B
Net Debt 1.01B 884M 817M 751M 1.42B 97.25B 1.44B 9.77B 3.83B 47.58B 3.79B 3.7B 164B 758M 664M 614M 565M 1.07B 73.09B 1.08B 7.34B 2.88B 35.76B 2.85B 2.78B 123B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
20/07/26 US$51.72 -1.90% 941,838
17/07/26 US$52.72 +1.50% 1,713,653
16/07/26 US$51.94 -0.08% 1,843,684
15/07/26 US$51.98 +0.74% 1,556,270
14/07/26 US$51.60 -0.52% 1,776,619
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
51.72USD
Average target price
52.65USD
Spread / Average Target
+1.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock